Ionis Reports Positive Long-Term Data for Olezarsen in Severe Hypertriglyceridemia
IONS has more than doubled off its 52-week low of $34.775.
Summary
Ionis Pharmaceuticals announced positive long-term data from its olezarsen open-label extension study, showing sustained reduction in liver fat and a favorable safety profile for patients with severe hypertriglyceridemia.
Key Events · Product Development and Regulatory · IONS
-
Positive Olezarsen Clinical Data
Ionis presented new positive data from the open-label extension study of olezarsen for severe hypertriglyceridemia (sHTG) at the National Lipid Association Scientific Sessions.
-
Sustained Liver Fat Reduction
The data showed mean hepatic fat fraction (HFF) levels returning toward baseline after 24 months of treatment with the 80 mg dose of olezarsen.
-
Favorable Safety Profile and High Retention
Olezarsen continued to demonstrate a favorable safety profile with longer-term treatment, and patient retention in the open-label extension study was very high, exceeding 90%.
Analysis · IONS · Life Sciences
Ionis Pharmaceuticals announced positive long-term data for olezarsen, demonstrating sustained reduction in hepatic fat fraction (HFF) over 24 months and a favorable safety profile in patients with severe hypertriglyceridemia. This data strengthens the drug's clinical profile, de-risking a key pipeline asset and reinforcing its potential for future regulatory approval and commercial success. High patient retention in the study further supports the drug's tolerability and perceived benefits.
At the time of this filing, IONS was trading at $73.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $34.78 to $86.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.